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Background: Osteopontin (OPN) is a pro-inflammatory cytokine which is expressed in various tissues. It participates
in the bone remodeling process and stimulates bone resorption by osteoclasts. It is also a core protein of cholesterol
gallstones. We hypothesized osteoporotic patients might have higher risk in developing gallstones and conducted a
population-based study to examine the risk of developing gallstone in osteoporotic patients in Taiwan.
Methods: A total of 1,638 patients diagnosed with osteoporosis between 2003 and 2005 were identified in the
National Health Insurance Research Database. A comparison cohort without osteoporosis (n =6,552) was randomly
matched to each osteoporosis patient at a ratio of 4: 1 based on age and sex. A Cox proportional-hazards regression
analysis was performed to evaluate the 5-year gallstone-free survival rates for the 2 cohorts.
Results: During the 5-year follow-up period, 114 and 311 cases of gallstone occurred in the osteoporosis and comparison
cohorts, respectively. After adjusting for the confounders, the Cox regression analysis of the risk of gallstone in the
osteoporosis and comparison cohorts yielded a hazard ratio of 1.35 (95% confidence interval: 1.07 - 1.69; p < 0 .01).
Conclusion: Patients with osteoporosis in Taiwan have a higher risk of developing gallstone than the general
population.
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Both osteoporosis and gallstone are diseases that affect
elderly patients worldwide. Osteoporosis is a chronic,
multifactorial, systemic skeletal disease characterized
by low bone density and an increased risk of bone frac-
tures [1]. Bone fracture is a major consequence of osteo-
porosis. Although osteoporosis was previously thought
to be associated with aging, the causes of osteoporosis
are related to the effects of inflammatory mediators and
endogenous hormones, such as estrogen deficiency [2].
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unless otherwise stated.caused by increased numbers of osteoclasts and in-
creased their activity [3]. Recent studies have also
demonstrated that pro-inflammatory cytokines, such as
interleukin (IL)-1, tumor necrosis factor-α, and IL-6, are
primary mediators of accelerated bone loss following
menopause [4]. In addition, the up-regulation of T lym-
phocytes are crucial in the stimulating osteoclasts in
post-menopausal bone loss [5].
Biliary calculus, also known as gallstone, is a crystal-
line solid formed from bile components that occurs
primarily in the gallbladder. Gallstone is a common and
costly disease and its complications consume about $6.5
billion in the United States [6]. Gallstones are classified
as cholesterol, pigment, or mixed stones [7] based on
whether the stones consist primarily of cholesterol, bili-
rubin, or calcium deposits. Environmental and genetic
factors, including female sex [8,9], family medical historyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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contribute to the development of gallstone.
Osteopontin (OPN) is a pro-inflammatory cytokine that
is expressed in various tissues involved in a wide range of
biological processes, such as bone mineralization, inflam-
mation, and cell survival [16]. It is expressed at high levels
in the bone matrix, and may promote the survival of auto-
reactive T cells [17] and participates in the bone remodel-
ing process [18]. One study showed that it stimulates the
adhesion, migration and bone resorption by osteoclasts
[19]. Fodor et al. found that high levels of OPN in post-
menopausal women are associated with low bone mineral
density, increased levels of bone turnover markers, and
osteoporotic vertebral fractures [20]. A recent study has
shown that OPN is also a core protein in the formation of
cholesterol gallstone [21]. Based on the studies mentioned
above, we hypothesized that osteoporotic patients might
have higher risk in developing gallstones, but the associ-
ation is not investigated. In the present study, we intended
to examine the relationship between osteoporosis and the




The National Health Insurance (NHI) program was im-
plemented in 1995, and provides reimbursements for
health-care costs to 99% of the 23 million residents of
Taiwan. Claims data are maintained in the National
Health Insurance Research Database (NHIRD), which is
managed by the National Health Research Institutes
(NHRI). Our study used the Longitudinal Health Insur-
ance Database (LHID2005), which is a subset of the
NHIRD. The LHID2005 database allows researchers to
follow-up all the medical service utilization for these 1
million enrollees that randomly selected from the
NHIRD in 2005. The NHRI claimed that there are no
statistically significant differences related to age, sex, or
health-care costs between the LHID2005 and the NHIRD.
We examined the ambulatory and inpatient care data for
patients in the LHID2005 from 1997 to 2010. The original
identification number of each patient in the LHID2005 is
encrypted to maintain patient privacy, and the encrypted
numbers are linked to the health-care data for each
patient. This study was exempt from full review by joint
institutional review board of Taipei Medical University
(TMU-JIRB No.201306039) because the LHID2005 con-
sist of de-identified secondary data released to the
public for research purposes.
Participants
We used a study cohort and a comparison cohort to retro-
spectively examine the relationship between osteoporosis
and gallstone. We identified patients aged 50 years orolder who were newly diagnosed with osteoporosis
between January 1, 2003, and December 31, 2005, based
on the diagnostic criteria of the International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM 733.X). The date of the first osteoporosis
diagnosis for each patient was assigned as their index
date for our study. To ensure the accuracy of the data,
only patients with ≥ 2 ambulatory visits or with ≥ 1 in-
patient visit for osteoporosis and receiving at least one
bone mineral density examination were included in the
osteoporotic cohort. Four patients without osteoporosis
were randomly matched based on age, sex, and the index
year to each patient in the osteoporosis cohort. Each
subject was tracked for five years from their index date to
identify whether they had suffered from a gallstone. The
definition of the gallstone cases in this study was that if
they received ≥ 2 gallstone diagnoses for ambulatory care
visit or ≥1 diagnosis for inpatient care, and received at
least one abdominal ultrasound examination. Patients
with a history of gallstone (ICD-9-CM 574.X) were ex-
cluded from our study. Hypertension (ICD-9-CM 401.X-
405.X), diabetes mellitus (ICD-9-CM 250.X), hyperlipid-
emia (ICD-9-CM 272.X), obesity (ICD-9-CM 278.X), liver
cirrhosis (ICD-9-CM 571.X), hemolytic anemia (ICD-9-
CM 282.X-283.X), spinal cord injury (ICD-9-CM 806.X,
907.2, 952.X), receiving hormone replacement therapy
or clofibrate or total parenteral nutrition over 30 days,
receiving ceftriaxone over 7 days, receiving short-acting
octreotide over 14 days and receiving long-acting octreo-
tide over 3 months were treated as covariates in our
analysis of the risk of gallstone.
Levels of urbanization
The 359 communities in Taiwan were stratified into 8
urbanization categories in the LHID 2005 according to
the criteria established by the NHRI, with 1 indicating
the most urbanized and 8 indicating the least urbanized.
The criteria included population density (persons per
km2), the percentage of people with a college-level edu-
cation or higher, the percentage of people aged 65 years
or older, the percentage of agricultural workers in the
local population, and the number of physicians per 100
000 population. However, because the number of osteo-
porosis cases in levels 5, 6, 7, and 8 were low, these
levels were combined into a single urbanization group,
level 5.
Statistical analysis
The parametric continuous data for the 2 cohorts was
compared using a Students t test, and the categorical
variables were evaluated using the chi-squared test.
Gallstone-free survival was calculated for all patients
diagnosed with osteoporosis from the date of the first
hospitalization or ambulatory visit for gallstone and the
Table 1 Demographic characteristics and comorbidities for the osteoporosis and comparison cohorts from 2003 to
2005 (N =8190)
Patients with osteoporosis (n =1638) Patients without osteoporosis (n =6552) P value
n % n %
Sex 1
Male 242 14.8 968 14.8
Female 1396 85.2 5584 85.2
Age (y) 1
50–64 648 39.6 2592 39.6
65–79 808 49.3 3232 49.3
≥ 80 182 11.1 728 11.1
Mean ± SD of follow-up (y) < .001
4.76 0.97 4.88 0.66
Urbanization level 0.037
1 (most urbanized) 443 27.0 2010 30.7
2 452 27.6 1688 25.8
3 229 14.0 929 14.2
4 264 16.1 1035 15.8
5 (least urbanized) 250 15.3 890 13.6
Monthly income 0.006
0 567 34.6 2520 38.5
NT$ 1–15,840 245 15.0 809 12.3
NT$ 15,841–25,000 695 42.4 2724 41.6
NT$ ≥25,001 131 8.0 499 7.6
Geographic region < .001
Northern 687 41.9 2953 45.1
Central 467 28.5 1630 24.9
Southern 355 21.7 1566 23.9
Eastern 129 7.9 403 6.2
Hypertension < .001
Yes 1212 74.0 4548 69.4
No 426 26.0 2004 30.6
Hyperlipidemia < .001
Yes 895 54.6 2914 44.5
No 743 45.4 3638 55.5
Diabetes 0.008
Yes 658 40.2 2399 36.6
No 980 59.8 4153 63.4
Liver cirrhosis < .001
Yes 368 22.5 900 13.7
No 1270 77.5 5652 86.3
Hemolytic anemia 0.773
Yes 2 0.1 10 0.2
No 1636 99.9 6542 99.8
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Table 1 Demographic characteristics and comorbidities for the osteoporosis and comparison cohorts from 2003 to
2005 (N =8190) (Continued)
Spinal cord injury <.001
Yes 99 6.0 17 0.3
No 1539 94.0 6535 99.7
Obesity 0.826
Yes 10 0.6 37 0.6
No 1628 99.4 6515 99.4
Hormone replacement <.001
Yes 231 14.1 298 4.5
No 1407 85.9 6254 95.5
Ceftriaxone 0.813
Yes 4 0.2 14 0.2
No 1634 99.8 6538 99.8
Clofibrate 0.045
Yes 1 0.1 Na Na
No 1637 99.9 6552 100.0
Octreotide 0.724
Yes 2 0.1 6 0.1
No 1636 99.9 6546 99.9
Total parenteral nutrition 0.070
Yes 1 0.1 21 0.3
No 1637 99.9 6531 99.7
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whichever came first. A Cox proportional-hazards re-
gression analysis stratified by sex, age group, and index
year was performed to examine the risk of gallstone in
the osteoporosis and comparison cohorts during the
5-year follow-up period. We also examined the effect of
sex, age, hypertension, diabetes, and hyperlipidemia on
the association between osteoporosis and gallstone
events. For the stratified Cox regression analysis, pa-
tients were divided into 3 categories, 50 to 64, 65 to 79,
or ≥ 80 years. The hazard ratios (HRs) and 95% confi-
dence intervals (CIs) were calculated to represent the
risk of gallstone in the cohorts before and after stratifi-
cation based on age or sex. We computed all study data
with Statistical Package for Social Science software
version 18 for Windows (SPSS Inc., Chicago, Illinois,
USA). The differences between compared groups were
considered significant if 2-side p-values were smaller
than 0.05.
Results
A total of 1,638 and 6,552 patients were included in the
osteoporosis and comparison cohorts, respectively. The
results of our analysis of the sociodemographic and
comorbidity data for the osteoporosis and comparison
cohorts are shown in Table 1. The osteoporotic patientshad higher rates of hypertension, hyperlipidemia, diabetes,
spinal cord injury, liver cirrhosis, receiving hormone
replacement therapy or clofibrate over 30 days than the
comparison cohort, and were more likely to have a
moderate monthly income or reside in central or eastern
Taiwan.
During the 5-year follow-up period, 114 (7.0%) of the
osteoporotic patients and 311 (4.7%) of the comparison
patients developed gallstones. The Cox regression analysis
showed that the crude HR of gallstone was 1.50 times
greater (95% CI: 1.21–1.86) for the osteoporosis patients
than that of the comparison cohort. The risk of gallstone
remained significant after adjusting for potential con-
founders (adjusted HR: 1.35, 95% CI: 1.07–1.69; Table 2),
and the osteoporosis patients had a significantly lower
5-year gallstone-free survival rate (p < 0 .001; Figure 1).
The overall gallstone incidence density was higher
among the patients with osteoporosis (14.62 per 1,000
person-years) than in the comparison cohort (9.73 per
1,000 person-years). The stratified analysis of incidence
showed that men had a higher incidence of gallstone than
women, and that patients aged 65 to 79 years had the
highest incidence of gallstone, compared with the pa-
tients ≤ 64 or ≥ 80 years of age in both groups (Table 3).
The stratified Cox regression analysis showed that
women with osteoporosis had a higher risk of gallstone
Table 2 Incidence of gallstone among the osteoporosis and comparison patients from 2003 to 2005 (N =8190)
Total Patients with osteoporosis Patients without osteoporosis
Gallstone cases n % n % n %
5-year follow-up period
Yes 425 5.2 114 7.0 311 4.7
No 7765 94.8 1524 93.0 6241 95.3
Crude HR (95% CI) 1.50 (1.21 - 1.86)* 1
Adjusted HR (95% CI) 1.35 (1.07 - 1.69)** 1
*p <0.001, **p <0.05.
Both crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional-hazard regressions stratified by age and sex.
Adjustments are made for sex, age, patients’ monthly income, region, urbanization level, hypertension, hyperlipidemia, diabetes, cirrhosis, spinal cord injury,
hormone replacement, and clofibrate.
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95% CI: 1.09 – 1.79, p < 0.01) (Table 3), and osteoporotic
patients who aged 50 to 64 years had higher risk of gall-
stone than non-osteoporotic subjects (adjusted HR: 1.56,
95% CI: 1.06 – 2.28, p < 0.01). No significant increased
risk was observed for patients aged 65- to 79-year-old or
above 80-year-old in either the osteoporosis or compari-
son cohorts.
Discussion
Our study is the first to demonstrate a relationship be-
tween osteoporosis and gallstone. Nearly 2,000 osteopor-
otic patients in Taiwan were collected in our current
study and compared with non-osteoporotic subjects. As
shown in Table 2, our results indicated that osteoporosis
was significantly associated with the risk of gallstone.
Osteoporosis and gallstone disease share similar epi-
demiological characteristic. Female sex is a risk factorFigure 1 Gallstone event-free survival rates for subjects with osteopofor both osteoporosis and gallstones. Sex hormones might
play an important role in the development of both osteo-
porosis and gallstone. D’Amelio et al. showed that estro-
gen deprivation induces bone loss by up-regulating
osteoclastogenesis, which contributes to the development
of osteoporosis [5]. Estrogen can promote the hepatic
secretion of biliary cholesterol that induces an increase in
cholesterol saturation of bile and then increases the risk
for the formation of cholesterol gallstones [22]. Our study
showed women were more among osteoporotic patients.
Women also had significantly higher incidence developing
gallstones and women with osteoporosis had a greater risk
of gallstones than women without osteoporosis. In addition,
although estrogen replacement is a common treatment for
osteoporosis in postmenopausal women, studies have
suggested that estrogen replacement therapy may be a risk
factor for gallstone [23]. Thus, estrogen replacement
therapy might affect the risk of gallstone in women withrosis and the comparison group from 2003 to 2005.
Table 3 Overall and age- and sex-specific incidence densities and relative hazard of gallstone in the osteoporosis and comparison cohorts
Factor Osteoporotic group Comparative group Crude HR Adjust HR
Incident cases Person-years ID1 95% CI Incident cases Person-years ID1 95% CI
Age (y)a
50-64 42 3080.05 13.64 9.54 - 17.73 103 12702.40 8.11 6.55 - 9.67 1.68 (1.17 - 2.40)** 1.56 (1.06 - 2.28)*
65-79 60 3846.65 15.60 11.68 - 19.51 170 15720.01 10.81 9.20 - 12.43 1.44 (1.07 - 1.94)* 1.25 (0.92 - 1.71)
≥ 80 12 868.91 13.81 6.05 - 21.57 38 3544.48 10.72 7.33 - 14.11 1.28 (0.67 - 2.46) 1.31 (0.64 - 2.68)
Sexb
Men 17 1142.92 14.87 7.86 - 21.89 48 4719.56 10.17 7.31 - 13.03 1.46 (0.84 - 2.54) 1.09 (0.60 - 1.96)
Women 97 6652.69 14.58 11.70 - 17.46 263 27247.33 9.65 8.49 - 10.81 1.51 (1.20 - 1.91)** 1.40 (1.09 - 1.79)**
Total 114 7795.61 14.62 11.96 - 17.29 311 31966.89 9.73 8.65 - 10.80 1.50 (1.21 - 1.86)*** 1.35 (1.07 - 1.69)*
*p <0.05,**p <0.01, ***p <0.001.
HR, hazard ratio; ID, incidence density (per 1000 patient-years); CI, confidence interval.
1Based on the Poisson assumption.
aAdjusted for sex, age, monthly income, region, urbanization level, hypertension, hyperlipidemia, diabetes, cirrhosis, spinal cord injury, hormone replacement, and clofibrate.
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result showed that osteoporotic patients still had signifi-
cantly higher risk in developing gallstones.
Age is another risk factor for both osteoporosis and
gallstones. Osteoporosis is highly prevalent, especially in
postmenopausal women. Approximately 46% of women
will experience at least one osteoporotic fracture after
the age of 50 years [24]. In Sirmione study, the incidence
of gallstones between the ages of 40–69 years was four
times higher than that in younger subjects [25]. The
population in our study was at higher risk to develop
gallstones because we included those age over 50 years
old. We used age-matched control group for following-
up. Hence, age would not be a confounding factor in our
study.
Other risk factors for the formation of gallstones include
family history, obesity, diabetes mellitus, hyperlipidemia,
liver cirrhosis, drugs, decreased physical activity, spinal
cord injury and hemolysis anemia. After adjusting
these confounding factors except family history and
decreased physical activity, patients with osteoporosis
remained having significantly higher risk in developing
gallstones than those without osteoporosis. Because
our study was based on NHIRD, family history and
physical activity cannot be retrieved from this dataset
and not all obesity subjects had a diagnosis of obesity.
These would be a limitation in our study. Despite of
this limitation, we eliminated the interference of most
possible risk factors for gallstones, and the result based
on the large sample size showed osteoporotic patients
are at higher risk to develop gallstones. Since the
complication of gallstones may cause high costs, more
effort should be invested in the population to reduce
such related cost.
Chronic inflammation might play a key role in the de-
velopment of gallstone. OPN is a pro-inflammatory cyto-
kine that is expressed in various tissues involved in a wide
range of biological processes [16]. OPN participates in the
bone remodeling process [18] and stimulates the adhesion,
migration and bone resorption by osteoclasts [19]. OPN is
also the core protein in cholesterol gallstones [26]. The
OPN molecule binds hydroxyapatite and calcium ions,
inhibiting the nucleation of cholesterol crystals in vivo.
Yang et al. showed that the OPN-mediated inhibition of
cholesterol stone nucleation is dose-dependent in an
animal model and in vitro using bile from human gall-
bladders [27]. In a mouse model of gallstone formation,
the level of OPN in the gallbladder wall increased before
the induction of inflammation [21]. Our results are con-
sistent with the findings of these previous studies, and
confirm the correlation between osteoporosis and gall-
stone disease. Future studies are warranted to identify
the role of OPN in the formation of gallstones in
patients with osteoporosis.Certain limitations to our study should be considered.
First, the NHIRD files did not provide information
regarding family history, physical activity and dietary
habits, all of which might be risk factors for gallstone.
Second, data regarding serum levels of osteopontin, sex
hormones, inflammatory mediators, and blood calcium
were also lacking. Third, not all over-weight subjects
would have a diagnosis of obesity in NHIRD. Obesity is
known to increase the risk of gallstone. Thus, we could
not completely exclude the interference of the risk
factor.
In our current study, we included much comorbidity
as risk factors in our analysis, and adjusted our Cox
regression model for them to avoid bias related to the
demographic characteristics of the osteoporosis patients.
Our study is the first nationwide population-based cohort
study with a large sample size to show that osteoporosis is
significantly associated with an increased risk for gallstone
in Taiwan. Our findings may provide important informa-
tion to aid medical care plans in the monitoring and pre-
vention of gallstone disease in osteoporosis patients. But
the biological mechanism underlying the contribution of
osteoporosis to gallstone remains unclear. Future studies
of gallstone in osteoporosis patients are needed to confirm
our findings.
Conclusions
This study indicated that osteoporosis patients are at a
higher risk of developing gallstone than the general
population.
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